MARKET

TARO

TARO

Taro Pharm
NYSE

Real-time Quotes | Nasdaq Last Sale

63.50
-1.33
-2.05%
Closed 16:00 09/20 EDT
OPEN
64.46
PREV CLOSE
64.83
HIGH
64.60
LOW
61.86
VOLUME
9.02K
TURNOVER
--
52 WEEK HIGH
80.00
52 WEEK LOW
53.95
MARKET CAP
2.41B
P/E (TTM)
83.42
1D
5D
1M
3M
1Y
5Y
Hemorrhoid Drugs Market- Global Size, Growth Insight, Share, Trends, Industry Key Players, Regional Forecast To 2029
Research Nester published a report titled " - Global Demand Analysis and Opportunity Outlook 2029" which delivers detailed overview of the hemorrhoid drugs market in terms of market segmentation by drug type, disease type, distribution channel, end-user an...
AmericaNewsHour · 23h ago
Techne (TECH) Soars to 52-Week High, Time to Cash Out?
Zacks.com · 09/03 13:15
Does The Market Have A Low Tolerance For Taro Pharmaceutical Industries Ltd.'s (NYSE:TARO) Mixed Fundamentals?
It is hard to get excited after looking at Taro Pharmaceutical Industries' (NYSE:TARO) recent performance, when its...
Simply Wall St. · 07/29 11:44
--HC Wainwright Adjusts Taro Pharmaceutical Industries' Price Target to $82 From $80, Keeps Buy Rating
MT Newswires · 07/28 10:22
Taro Pharmaceutical Fiscal Q1 Adjusted Earnings Per Share, Revenue Rise
MT Newswires · 07/28 06:18
Taro Pharmaceutical EPS beats by $0.25, beats on revenue
Taro Pharmaceutical (TARO): Q2 Non-GAAP EPS of $1.09 beats by $0.25; GAAP EPS of -$0.50 misses by $1.34.Revenue of $147.1M (+25.1% Y/Y) beats by $9.87M.Settlements and loss contingencies of $60.0
Seekingalpha · 07/28 05:01
BRIEF-Taro Reports Qtrly Loss Per Share $0.50
reuters.com · 07/28 01:26
Taro Pharmaceutical (TARO) Q1 Earnings and Revenues Beat Estimates
Taro (TARO) delivered earnings and revenue surprises of 29.76% and 7.23%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 07/28 00:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TARO. Analyze the recent business situations of Taro Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TARO stock price target is 82.00 with a high estimate of 82.00 and a low estimate of 82.00.
EPS
Institutional Holdings
Institutions: 133
Institutional Holdings: 5.27M
% Owned: 13.89%
Shares Outstanding: 37.93M
TypeInstitutionsShares
Increased
19
220.87K
New
7
113.25K
Decreased
30
346.72K
Sold Out
11
67.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.35%
Pharmaceuticals & Medical Research
-1.08%
Key Executives
Chairman/Director
Dilip Shanghvi
Chief Executive Officer/Director
Uday Baldota
Vice Chairman/Director
Abhay Gandhi
Vice President/General Counsel/Secretary
Erik Zwicker
Vice President/Director of Human Resources
Michele Visosky
Vice President
Victoria Chester
Vice President
Itamar Karsenti
Vice President - Research & Development
Avi Avramoff
Vice President - Business Development
Vikash Agarwal
Other
Jayesh Shah
Director
James Kedrowski
Director
Sudhir Valia
Independent Director
Linda Benshoshan
Independent Director
Dov Pekelman
Independent Director
Robert Stein
Declaration Date
Dividend Per Share
Ex-Div Date
11/05/2018
Dividend USD 0
12/10/2018
11/05/2018
Special Dividend USD 12.81
12/10/2018
About TARO
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc. (Taro Canada) and Taro U.S.A. The Company markets over 200 pharmaceutical products in over 25 countries. The Company's owned product brands include Rokacet, with generic names, such as acetaminophen, codeine and caffeine; Topicort, with the generic name, desoximetasone; Etopan, with the generic name etodolac, and Ovide, with the generic name, malathion, among others. The Company's other generic products include acetazolamide, adapalene, alclometasone dipropionate, amiodarone hydrochloride, ammonium lactate, augmented betamethasone dipropionate, cetirizine hydrochloride, clobetasol propionate, clomipramine hydrochloride, clorazepate dipotassium, fluorouracil, ketoconazole, metronidazole, mupirocin and warfarin sodium, among others.

Webull offers kinds of Taro Pharmaceutical Industries Ltd. stock information, including NYSE:TARO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TARO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TARO stock methods without spending real money on the virtual paper trading platform.